The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
 
Diarmuid Martin Moran
Employment - Astellas Pharma
 
Abraham Guerrero
Employment - Astellas Pharma
 
Yoko Ueno
Employment - Astellas Pharma
Stock and Other Ownership Interests - Astellas Pharma
 
Jung Wook Park
Employment - Astellas Pharma
 
Janet Pavese
Employment - Astellas Pharma
 
Yuichiro Kaneko
Employment - Astellas Pharma
 
Maria Matsangou
Employment - Astellas Pharma
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)